Unlike Johnson & Johnson’s (J&J’s) first-quarter earnings report the previous week, which was met with a stock price fall, Novartis AG’s first-quarter earnings announcement was accompanied by a 4% stock price rise to a dizzy three-year high. By comparison, the NYSE Arca Pharmaceutical Index (DRG) finished barely in positive territory on the same day.
Novartis’s first-quarter 2023 net sales grew by just over 3% on the same quarter of 2022 while earnings per share...








